Paper Details

  1. Home
  2. Paper Details

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.

Author: GottliebAlice, HugotSophie, KubanovAlexey, MilutinovicMarina, ParneixAnne, SullivanJohn, YouRuquan, van DoornMartijn

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Secukinumab, an anti-interleukin 17A antibody, demonstrated significant efficacy in treating palmoplantar psoriasis, with 33.3% of patients achieving clear or almost clear palms and soles at week 16 with 300mg and 22.1% with 150mg compared to 1.5% with placebo. The safety profile was favorable.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Plaque psoriasis affecting palms and soles is disabling and often resistant to treatment. OBJECTIVE: Evaluate the efficacy and safety of secukinumab, an anti-interleukin 17A antibody, in subjects with palmoplantar psoriasis. METHODS: In this double-blinded, randomized controlled trial,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jaad.2016.07.058

データ提供：米国国立医学図書館（NLM）

Secukinumab: A Promising Oasis in the Desert of Palmoplantar Psoriasis

Palmoplantar psoriasis is a debilitating skin condition, like a harsh desert wind that relentlessly attacks the body. This study investigates the effectiveness and safety of secukinumab, an anti-interleukin 17A antibody, in treating this challenging disease.

The study involved 205 patients randomized to receive either secukinumab 300 mg, 150 mg, or placebo. The researchers found that both doses of secukinumab significantly improved palmoplantar psoriasis symptoms, offering a beacon of hope for those struggling with this condition. It's like discovering a hidden oasis in the desert, providing relief and healing.

Secukinumab's Effectiveness in Palmoplantar Psoriasis

At week 16, the percentage of patients achieving clear or almost clear palms and soles was significantly higher in both secukinumab groups compared to placebo. It's like watching a desert bloom after a rare rainfall, witnessing the transformative power of this treatment.

Hope for Palmoplantar Psoriasis Patients

Secukinumab offers a promising new treatment option for palmoplantar psoriasis, providing relief from symptoms and improving quality of life. It's like finding a refreshing spring in a parched desert, offering hope for a brighter future.

Dr. Camel's Conclusion

Secukinumab demonstrates significant efficacy in treating palmoplantar psoriasis, offering a much-needed oasis of relief for those struggling with this challenging condition. It's a testament to the power of scientific innovation to find solutions in even the harshest deserts of disease.

Date :
  1. Date Completed 2017-04-24
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

27707593

DOI: Digital Object Identifier

10.1016/j.jaad.2016.07.058

Related Literature

Article Analysis
・Effective treatment of psoriasis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.